Theravance Biopharma (TBPH) to Release Earnings on Wednesday

Theravance Biopharma (NASDAQ:TBPH) is expected to announce its Q4 2025 results before the market opens on Wednesday, February 25th. Analysts expect the company to announce earnings of $0.44 per share for the quarter. Individuals can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Monday, February 23, 2026 at 4:00 PM ET.

Theravance Biopharma Trading Down 3.7%

NASDAQ TBPH opened at $18.81 on Wednesday. Theravance Biopharma has a 1-year low of $7.90 and a 1-year high of $21.03. The stock’s 50 day moving average is $19.18 and its two-hundred day moving average is $16.41. The company has a market capitalization of $953.14 million, a price-to-earnings ratio of 33.00 and a beta of 0.15.

Insider Buying and Selling

In other news, SVP Rhonda Farnum sold 31,067 shares of the company’s stock in a transaction on Wednesday, December 3rd. The stock was sold at an average price of $18.75, for a total transaction of $582,506.25. Following the transaction, the senior vice president owned 277,695 shares of the company’s stock, valued at $5,206,781.25. This represents a 10.06% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Insiders own 6.90% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in TBPH. Quarry LP bought a new stake in shares of Theravance Biopharma during the third quarter worth approximately $26,000. Caitong International Asset Management Co. Ltd grew its holdings in Theravance Biopharma by 107.4% during the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 2,725 shares of the biopharmaceutical company’s stock worth $40,000 after acquiring an additional 1,411 shares during the period. CIBC Private Wealth Group LLC lifted its stake in shares of Theravance Biopharma by 20,269.6% in the 3rd quarter. CIBC Private Wealth Group LLC now owns 4,685 shares of the biopharmaceutical company’s stock valued at $68,000 after purchasing an additional 4,662 shares during the period. Tower Research Capital LLC TRC lifted its stake in shares of Theravance Biopharma by 18.5% in the 2nd quarter. Tower Research Capital LLC TRC now owns 5,013 shares of the biopharmaceutical company’s stock valued at $55,000 after purchasing an additional 781 shares during the period. Finally, Virtus Advisers LLC acquired a new stake in shares of Theravance Biopharma during the fourth quarter worth $170,000. 99.10% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

TBPH has been the subject of several recent analyst reports. Wall Street Zen lowered Theravance Biopharma from a “strong-buy” rating to a “buy” rating in a research note on Saturday, January 3rd. HC Wainwright increased their target price on shares of Theravance Biopharma from $15.00 to $20.00 and gave the stock a “buy” rating in a research report on Tuesday, November 11th. Weiss Ratings reissued a “hold (c)” rating on shares of Theravance Biopharma in a report on Thursday, January 22nd. BTIG Research reaffirmed a “buy” rating and set a $40.00 price objective on shares of Theravance Biopharma in a research note on Tuesday, February 3rd. Finally, Oppenheimer began coverage on shares of Theravance Biopharma in a report on Wednesday, December 3rd. They set an “outperform” rating and a $27.00 price objective for the company. Two investment analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat, Theravance Biopharma currently has a consensus rating of “Buy” and an average price target of $27.80.

Theravance Biopharma Company Profile

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.